Skip to content

Rheumatoid arthritis — JAK inhibitors and targeted therapy

TL;DR — JAK inhibitors are oral targeted synthetic DMARDs that interrupt signaling from multiple cytokine receptors and can act rapidly after conventional or biologic failure. Upadacitinib was superior to adalimumab for selected endpoints in SELECT-COMPARE (1,629 patients) and to abatacept in SELECT-CHOICE, but more efficacy does not erase risk (Fleischmann 2019, PMID 31287230; Rubbert-Roth 2020, PMID 33053283). In ORAL Surveillance, 4,362 RA patients aged ≥50 with at least one cardiovascular risk factor received tofacitinib or TNF inhibitors; tofacitinib failed noninferiority for major cardiovascular events and cancer (Ytterberg 2022, PMID 35081280). The excess is clearest in the enriched population and should not be mechanically generalized to every patient, but regulators and guidelines now require risk-stratified positioning. Herpes zoster, serious infection, venous thrombosis, lipids, cytopenias and liver abnormalities complete the monitoring frame.

Agents and signaling

Agent Relative biochemical preference RA status varies by region Core class issues
Tofacitinib JAK1/JAK3 Widely approved ORAL Surveillance evidence base
Baricitinib JAK1/JAK2 Approved in many regions VTE and infection warnings
Upadacitinib JAK1-preferential Widely approved Strong head-to-head efficacy; class warnings
Filgotinib JAK1-preferential Approved in some regions, not US RA Region-specific reproductive/regulatory history
Peficitinib Pan-JAK Approved in selected Asian markets Smaller global evidence base

Selectivity is dose-, cell- and cytokine-dependent; in vitro labels do not map cleanly to clinical safety. All inhibit overlapping cytokine signaling, particularly IL-6-related pathways (Kubo 2023, PMID 37014106; Traves 2021, PMID 33741556).

Efficacy

SELECT-COMPARE randomized 1,629 methotrexate-inadequate responders to upadacitinib, placebo or adalimumab with background methotrexate; upadacitinib met clinical and radiographic endpoints and was superior to adalimumab for prespecified comparisons (Fleischmann 2019, PMID 31287230). SELECT-CHOICE compared upadacitinib with abatacept after biologic failure and found greater DAS28-CRP improvement at week 12, with more serious adverse events in the upadacitinib group (Rubbert-Roth 2020, PMID 33053283).

ORAL Strategy showed tofacitinib plus methotrexate was noninferior to adalimumab plus methotrexate, while tofacitinib monotherapy did not establish noninferiority to the combinations (Fleischmann 2017, PMID 28629665).

Evidence context What can be concluded What cannot
Placebo-controlled RCT Drug efficacy over placebo Comparative long-term safety
Active head-to-head RCT Relative short-term efficacy Rare-event certainty
ORAL Surveillance Comparative risk in enriched older CV-risk population Exact risk in young low-risk patients
Registry Longer, broader exposure Fully remove channeling/confounding
Meta-analysis across diseases More events and power Preserve RA-specific baseline risk

ORAL Surveillance

The trial enrolled patients aged at least 50 with ≥1 cardiovascular risk factor and compared two tofacitinib doses with TNF inhibition. Noninferiority margins were not met for MACE or malignancy excluding nonmelanoma skin cancer; the evidence changed the class’s regulatory and guideline positioning (Ytterberg 2022, PMID 35081280).

Risk dimension Interpretation
Age Trial explicitly enriched older patients
Smoking Current/past smoking contributed to higher-risk strata
Established ASCVD Raises absolute MACE risk and likely treatment-risk relevance
Cancer history/risk Requires individualized assessment
VTE history/risk Important across the class
Dose Higher tofacitinib dose had specific thromboembolic concern
Comparator Harm signal is versus TNF inhibitors, not untreated RA

Meta-analysis across JAK indications found malignancy more frequent versus TNF inhibitors but not clearly versus placebo or methotrexate, illustrating comparator dependence (Russell 2023, PMID 37247942).

Infection and laboratory effects

Herpes zoster is a consistent class signal. Serious infection risk is shaped by age, glucocorticoids, comorbidity, lymphocyte count and combination immunosuppression. TB, hepatitis and vaccination review precede treatment.

Monitoring Reason
CBC Lymphopenia, neutropenia, anemia
Liver enzymes Drug-related abnormalities and interactions
Lipids Predictable increases; manage global CV risk
Renal/hepatic function Agent-specific dosing
Skin examination/risk review Malignancy surveillance context
Infection symptoms Rapid interruption/assessment when indicated
VTE symptoms Urgent evaluation for unilateral swelling, chest pain or dyspnea

Positioning

EULAR 2022 places JAK inhibitors alongside biologics after inadequate conventional therapy but requires pertinent risk-factor consideration; ACR 2021 predates the final ORAL Surveillance publication and must be interpreted in that chronology (Smolen 2023, PMID 36357155; Fraenkel 2021, PMID 34101376).

JAK inhibitors may be attractive when oral administration, rapid onset, short pharmacologic half-life or prior biologic failure matter. They are less attractive when older age, smoking, established cardiovascular disease, malignancy risk, recurrent serious infection or VTE risk dominates. This is risk stratification, not a claim that TNF inhibitors are risk-free.

RA-ILD uncertainty

A 2024 meta-analysis found only seven observational studies of JAK inhibitors in RA-ILD plus three studies of incident ILD; this is insufficient for confident lung-specific comparative effectiveness (Narváez 2024, PMID 39270812). Joint efficacy should not be mistaken for proven antifibrotic efficacy.

Efficacy–safety tension quantified

Evidence Estimate Boundary
FINCH 2 after biologic failure At week 12, ACR20 was 66.0% with filgotinib 200 mg, 57.5% with 100 mg, and 31.1% with placebo; absolute differences 34.9% (95% CI 23.5–46.3) and 26.4% (15.0–37.9) (Genovese 2019, PMID 31334793). Short placebo comparison establishes efficacy, not comparative long-term safety.
Randomized VTE evidence across immune-mediated disease 42 trials yielded 15 VTEs over 6,542 JAK-inhibitor patient-years and 4 over 1,578 placebo patient-years; pooled IRR 0.68 (95% CI 0.36–1.29) (Yates 2021, PMID 33174384). Sparse events, younger trial populations and short follow-up cannot negate the risk-enriched ORAL Surveillance result.
JAK versus TNF synthesis Across 215,278 patients, MACE OR was 0.87 (95% CI 0.64–1.17); across 176,951, VTE OR was 1.28 (0.89–1.84) (Partalidou 2024, PMID 38756933). Mixing randomized and observational designs can dilute effect modification by age, smoking, and baseline cardiovascular risk.
Real-world herpes zoster Swedish ARTIS data found HR 3.82 (95% CI 2.05–7.09) for baricitinib and 4.00 (1.59–10.06) for tofacitinib versus etanercept (Frisell 2023, PMID 36787994). This is a drug-specific, preventable infection signal, not proof of a uniform class effect for every outcome.
Infection network meta-analysis Apparent between-JAK differences in herpes zoster lost significance in sensitivity analyses (Alves 2022, PMID 33902098). Ranking rare harms from indirect comparisons is unstable.

Five-year SELECT-COMPARE follow-up supplies durability data for upadacitinib versus adalimumab (Fleischmann 2024, PMID 38806190), while FINCH 3 tested filgotinib with or without methotrexate in patients with limited prior methotrexate exposure (Westhovens 2021, PMID 33452004). Neither resolves the policy controversy created by ORAL Surveillance: regulators and guidelines reasonably extrapolate a risk-enriched tofacitinib comparison to a precautionary class posture, whereas pooled trials and some registries find smaller or nonsignificant average differences. Risk is therefore conditional, not binary.

Evidence map

This map adds directly adjacent evidence used to bound interpretation. Inclusion means the record informs this topic or a tightly linked decision; it does not imply that every study supports every conclusion on the page.

Adjacent evidence Relevance to this page
Lipsky PE, et al. Infliximab and methotrexate in rheumatoid arthritis. N Engl J Med. 2000. (PMID 11096166) Adjacent evidence from biologic-dmards.md, classification-and-diagnosis.md, epidemiology-and-burden.md, overview.md, synovial-immunobiology.md
Breedveld FC, et al. PREMIER: adalimumab plus methotrexate versus monotherapies. Arthritis Rheum. 2006;54:26-37. (PMID 16385520) Adjacent evidence from biologic-dmards.md, synovial-immunobiology.md
Klareskog L, et al. Etanercept plus methotrexate versus each alone: TEMPO. Lancet. 2004;363:675-681. (PMID 15001324) Adjacent evidence from biologic-dmards.md, synovial-immunobiology.md
Gabay C, et al. Tocilizumab versus adalimumab monotherapy: ADACTA. Lancet. 2013;381:1541-1550. (PMID 23515142) Adjacent evidence from biologic-dmards.md, synovial-immunobiology.md
Jones G, et al. Tocilizumab versus methotrexate monotherapy: AMBITION. Ann Rheum Dis. 2010;69:88-96. (PMID 19297346) Adjacent evidence from biologic-dmards.md, synovial-immunobiology.md
Cohen SB, et al. Rituximab after anti-TNF failure: REFLEX. Arthritis Rheum. 2006;54:2793-2806. (PMID 16947627) Adjacent evidence from biologic-dmards.md, synovial-immunobiology.md
Fleischmann R, et al. Abatacept and adalimumab in early RA with poor prognostic factors: AMPLE. Rheumatol Ther. 2019;6:559-571. (PMID 31642045) Adjacent evidence from biologic-dmards.md, synovial-immunobiology.md
Rech J, et al. ARIAA abatacept prevention trial. Lancet. 2024. (PMID 38364841) Adjacent evidence from biologic-dmards.md, clinical-trials-landscape.md, epidemiology-and-burden.md, genetics-environment-and-mucosal-origins.md, overview.md, preclinical-autoimmunity-and-prevention.md, synovial-immunobiology.md
Cope AP, et al. APIPPRA abatacept prevention trial. Lancet. 2024. (PMID 38364839) Adjacent evidence from biologic-dmards.md, clinical-trials-landscape.md, epidemiology-and-burden.md, genetics-environment-and-mucosal-origins.md, overview.md, preclinical-autoimmunity-and-prevention.md, synovial-immunobiology.md
Lee YH, et al. Tocilizumab, rituximab, abatacept and tofacitinib after TNF failure: network meta-analysis. Rheumatol Int. 2016. (PMID 26692536) Adjacent evidence from biologic-dmards.md, synovial-immunobiology.md
Sung YK, et al. Comparative biologic efficacy after TNF-inhibitor failure. Int J Clin Pharmacol Ther. 2022. (PMID 34622767) Adjacent evidence from biologic-dmards.md, synovial-immunobiology.md
Tarp S, et al. Serious adverse effects of biologic and targeted drugs in RA. Rheumatology. 2017. (PMID 28013201) Adjacent evidence from biologic-dmards.md
Rivellese F, et al. Synovial biopsy biomarker analysis of R4RA. Nat Med. 2022. (PMID 35589854) Adjacent evidence from biologic-dmards.md, biomarkers-and-tissue-precision.md, clinical-trials-landscape.md, conventional-dmards.md, genetics-environment-and-mucosal-origins.md, preclinical-autoimmunity-and-prevention.md, synovial-immunobiology.md, treat-to-target-and-remission.md
Jang S, et al. Pathogenic roles of diverse immune cells in RA. Int J Mol Sci. 2022. (PMID 35055087) Adjacent evidence from biologic-dmards.md, classification-and-diagnosis.md, epidemiology-and-burden.md, overview.md, synovial-immunobiology.md
Schonfeldova B, et al. Synovial single-cell heterogeneity and zonation. Nat Rev Rheumatol. 2022. (PMID 34559213) Adjacent evidence from biologic-dmards.md, biomarkers-and-tissue-precision.md, genetics-environment-and-mucosal-origins.md, preclinical-autoimmunity-and-prevention.md, synovial-immunobiology.md
Cheng L, et al. New insights from single-cell sequencing: synovial fibroblasts and macrophages in RA. Front Immunol. 2021. (PMID 34349767) Adjacent evidence from biologic-dmards.md, synovial-immunobiology.md
Knab K, et al. Synovial macrophage and fibroblast heterogeneity in joint homeostasis and inflammation. Front Immunol. 2022. (PMID 35547214) Adjacent evidence from biologic-dmards.md, synovial-immunobiology.md
Kemble S, et al. Critical role of synovial tissue-resident macrophage and fibroblast subsets. Front Immunol. 2021. (PMID 34539648) Adjacent evidence from biologic-dmards.md, synovial-immunobiology.md
Pap T, et al. Role of synovial fibroblasts in RA pathogenesis. Arthritis Res. 2000. (PMID 11094449) Adjacent evidence from biologic-dmards.md, synovial-immunobiology.md
Evidence-map records are listed in full below and were live-retrieved from PubMed in this build session.

Open questions

  • Are MACE/cancer risks molecule-specific, dose-specific or a class property? (Ytterberg 2022, PMID 35081280)
  • What is the absolute excess risk in patients under 50 without smoking or cardiovascular disease?
  • Can biomarkers predict who gains the incremental efficacy without incremental harm?
  • How should JAK inhibitors be sequenced after one versus multiple biologic failures?
  • Do JAK inhibitors stabilize RA-ILD compared with biologics in an adequately controlled trial? (Narváez 2024, PMID 39270812)

References

  1. Fleischmann R, et al. Upadacitinib Versus Placebo or Adalimumab in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase III, Double-Blind, Randomized Controlled Trial. Arthritis Rheumatol. 2019;71:1788-1800. PMID 31287230
  2. Rubbert-Roth A, et al. Trial of Upadacitinib or Abatacept in Rheumatoid Arthritis. N Engl J Med. 2020;383:1511-1521. PMID 33053283
  3. Ytterberg SR, et al. Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis. N Engl J Med. 2022;386:316-326. PMID 35081280
  4. Kubo S, et al. JAK inhibitors for rheumatoid arthritis. Expert Opin Investig Drugs. 2023;32:333-344. PMID 37014106
  5. Traves PG, et al. JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib. Ann Rheum Dis. 2021;80:865-875. PMID 33741556
  6. Fleischmann R, et al. Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial. Lancet. 2017;390:457-468. PMID 28629665
  7. Russell MD, et al. JAK inhibitors and the risk of malignancy: a meta-analysis across disease indications. Ann Rheum Dis. 2023;82:1059-1067. PMID 37247942
  8. Smolen JS, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023;82:3-18. PMID 36357155
  9. Fraenkel L, et al. 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Rheumatol. 2021;73:1108-1123. PMID 34101376
  10. Narváez J, et al. Janus kinase inhibitors in rheumatoid arthritis-associated interstitial lung disease: A systematic review and meta-analysis. Autoimmun Rev. 2024;23:103636. PMID 39270812
  11. Genovese MC, et al. Effect of Filgotinib vs Placebo on Clinical Response in Patients With Moderate to Severe Rheumatoid Arthritis Refractory to Disease-Modifying Antirheumatic Drug Therapy: The FINCH 2 Randomized Clinical Trial. JAMA. 2019;322:315-325. PMID 31334793
  12. Yates M, et al. Venous Thromboembolism Risk With JAK Inhibitors: A Meta-Analysis. Arthritis Rheumatol. 2021;73:779-788. PMID 33174384
  13. Partalidou S, et al. Risk of Major Adverse Cardiovascular Events and Venous Thromboembolism with JAK Inhibitors versus TNF Inhibitors in Rheumatoid Arthritis Patients: A Systematic Review and Meta-Analysis. Mediterr J Rheumatol. 2024;35:10-19. PMID 38756933
  14. Frisell T, et al. Safety of biological and targeted synthetic disease-modifying antirheumatic drugs for rheumatoid arthritis as used in clinical practice: results from the ARTIS programme. Ann Rheum Dis. 2023;82:601-610. PMID 36787994
  15. Alves C, et al. The Risk of Infections Associated With JAK Inhibitors in Rheumatoid Arthritis: A Systematic Review and Network Meta-analysis. J Clin Rheumatol. 2022;28:e407-e414. PMID 33902098
  16. Fleischmann R, et al. Long-term safety and efficacy of upadacitinib versus adalimumab in patients with rheumatoid arthritis: 5-year data from the phase 3, randomised SELECT-COMPARE study. RMD Open. 2024;10:e004007. PMID 38806190
  17. Westhovens R, et al. Filgotinib in combination with methotrexate or as monotherapy versus methotrexate monotherapy in patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: the phase 3, randomised controlled FINCH 3 trial. Ann Rheum Dis. 2021;80:727-738. PMID 33452004
  18. Lipsky PE, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med. 2000;343:1594-602. PMID 11096166
  19. Breedveld FC, et al. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum. 2006;54:26-37. PMID 16385520
  20. Klareskog L, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet. 2004;363:675-81. PMID 15001324
  21. Gabay C, et al. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial. Lancet. 2013;381:1541-50. PMID 23515142
  22. Jones G, et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis. 2010;69:88-96. PMID 19297346
  23. Cohen SB, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum. 2006;54:2793-806. PMID 16947627
  24. Fleischmann R, et al. Efficacy of Abatacept and Adalimumab in Patients with Early Rheumatoid Arthritis With Multiple Poor Prognostic Factors: Post Hoc Analysis of a Randomized Controlled Clinical Trial (AMPLE). Rheumatol Ther. 2019;6:559-571. PMID 31642045
  25. Rech J, et al. Abatacept inhibits inflammation and onset of rheumatoid arthritis in individuals at high risk (ARIAA): a randomised, international, multicentre, double-blind, placebo-controlled trial. Lancet. 2024;403:850-859. PMID 38364841
  26. Cope AP, et al. Abatacept in individuals at high risk of rheumatoid arthritis (APIPPRA): a randomised, double-blind, multicentre, parallel, placebo-controlled, phase 2b clinical trial. Lancet. 2024;403:838-849. PMID 38364839
  27. Lee YH, et al. Comparative efficacy and safety of tocilizumab, rituximab, abatacept and tofacitinib in patients with active rheumatoid arthritis that inadequately responds to tumor necrosis factor inhibitors: a Bayesian network meta-analysis of randomized controlled trials. Int J Rheum Dis. 2016;19:1103-1111. PMID 26692536
  28. Sung YK, et al. Comparative efficacy and safety of biologic agents in patients with active rheumatoid arthritis and inadequate response to tumor necrosis factor inhibitors: A Bayesian network meta-analysis of randomized controlled trials. Int J Clin Pharmacol Ther. 2022;60:13-23. PMID 34622767
  29. Tarp S, et al. Risk of serious adverse effects of biological and targeted drugs in patients with rheumatoid arthritis: a systematic review meta-analysis. Rheumatology (Oxford). 2017;56:417-425. PMID 28013201
  30. Rivellese F, et al. Rituximab versus tocilizumab in rheumatoid arthritis: synovial biopsy-based biomarker analysis of the phase 4 R4RA randomized trial. Nat Med. 2022;28:1256-1268. PMID 35589854
  31. Jang S, et al. Rheumatoid Arthritis: Pathogenic Roles of Diverse Immune Cells. Int J Mol Sci. 2022;23:905. PMID 35055087
  32. Schonfeldova B, et al. Synovial single-cell heterogeneity, zonation and interactions: a patchwork of effectors in arthritis. Rheumatology (Oxford). 2022;61:913-925. PMID 34559213
  33. Cheng L, et al. New Insights From Single-Cell Sequencing Data: Synovial Fibroblasts and Synovial Macrophages in Rheumatoid Arthritis. Front Immunol. 2021;12:709178. PMID 34349767
  34. Knab K, et al. Synovial Macrophage and Fibroblast Heterogeneity in Joint Homeostasis and Inflammation. Front Med (Lausanne). 2022;9:862161. PMID 35547214
  35. Kemble S, et al. Critical Role of Synovial Tissue-Resident Macrophage and Fibroblast Subsets in the Persistence of Joint Inflammation. Front Immunol. 2021;12:715894. PMID 34539648
  36. Pap T, et al. Fibroblast biology. Role of synovial fibroblasts in the pathogenesis of rheumatoid arthritis. Arthritis Res. 2000;2:361-7. PMID 11094449